{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:35:28Z","timestamp":1792758928684,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Two registry studies, RETRO and PROSPECT, were conducted to evaluate real-world safety and effectiveness outcomes in US participants with sickle cell disease (SCD) who received voxelotor as standard of care. RETRO collected retrospective data of participants aged \u226512 years at 9 US sites for \u223c1 year after voxelotor initiation. PROSPECT collected retrospective and prospective data of participants aged \u22654 years at 24 US sites, with a 5-year follow-up planned. Both studies collected data for 1 year before voxelotor initiation. RETRO enrolled 216 participants. PROSPECT enrolled 265 participants before voxelotor was withdrawn from global markets in September 2024; of these, 260 participants received voxelotor. The mean \u00b1 standard deviation (SD) voxelotor treatment duration was 50.52 \u00b1 25.1 and 143.2 \u00b1 65.6 weeks in RETRO and PROSPECT, respectively. Safety analyses included all participants who received voxelotor. The mean \u00b1 SD observed change in hemoglobin from baseline was from 0.6 \u00b1 1.6 to 0.8 \u00b1 1.5 g\/dL in RETRO (\u223c1 year) and from 0.1 \u00b1 1.7 to 0.7 \u00b1 1.5 g\/dL in PROSPECT (54 months). After starting voxelotor, decreases were observed from baseline in hemolysis markers (absolute\/percentage reticulocyte counts, total\/indirect bilirubin) across all RETRO time points and most PROSPECT time points. Acute pain crisis (APC) was the most common SCD complication (annualized incidence rates before and after voxelotor, respectively: RETRO: 1.33 and 1.54; PROSPECT 4.78 and 3.15). No new safety findings were identified. Despite inherent limitations of registry studies, voxelotor treatment increased hemoglobin and decreased hemolysis markers in US clinical practice, with no evidence of increased frequency of APC. These studies were registered at www.ClinicalTrials.gov as NCT04930328 and NCT04930445.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018992","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T22:05:55Z","timestamp":1771365955000},"page":"3032-3043","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Safety and effectiveness of voxelotor in individuals with sickle cell disease in the RETRO and PROSPECT US registries"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-6037","authenticated-orcid":false,"given":"Biree","family":"Andemariam","sequence":"first","affiliation":[{"name":"1New England Sickle Cell Institute, University of Connecticut Health, Farmington, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7506-0935","authenticated-orcid":false,"given":"Nirmish","family":"Shah","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8160-7661","authenticated-orcid":false,"given":"William B.","family":"Ershler","sequence":"additional","affiliation":[{"name":"3Inova Schar Cancer Institute, Falls Church, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Donnell","family":"Ivy","sequence":"additional","affiliation":[{"name":"4Sickle Cell Association of America, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika S.","family":"Darbari","sequence":"additional","affiliation":[{"name":"5Children\u2019s National Hospital, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Anderson","sequence":"additional","affiliation":[{"name":"6Department of Pediatric Hematology-Oncology, PRISMA Health-Upstate Comprehensive SCD Program, Greenville, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5770-7280","authenticated-orcid":false,"given":"Parul","family":"Rai","sequence":"additional","affiliation":[{"name":"7Department of Hematology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6383-7172","authenticated-orcid":false,"given":"Ted","family":"Wun","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Oncology, UC Davis School of Medicine, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Ray","family":"Yu","sequence":"additional","affiliation":[{"name":"9Pfizer Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Purdie","sequence":"additional","affiliation":[{"name":"9Pfizer Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen M.","family":"Valenzuela","sequence":"additional","affiliation":[{"name":"9Pfizer Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2382-9230","authenticated-orcid":false,"given":"Michelle","family":"Xu","sequence":"additional","affiliation":[{"name":"9Pfizer Inc, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"2026051915113094300_bib1","volume-title":"StatPearls","author":"Borhade","year":"2025"},{"issue":"2","key":"2026051915113094300_bib2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/ijns5020020","article-title":"Sickle cell disease-genetics, pathophysiology, clinical presentation and treatment","volume":"5","author":"Inusa","year":"2019","journal-title":"Int J Neonatal Screen"},{"issue":"1","key":"2026051915113094300_bib3","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2026051915113094300_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ajh.24235","article-title":"Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: the last 40 years","volume":"91","author":"Chaturvedi","year":"2016","journal-title":"Am J Hematol"},{"issue":"6 suppl 4","key":"2026051915113094300_bib5","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1016\/j.amepre.2011.09.006","article-title":"Disability among individuals with sickle cell disease: literature review from a public health perspective","volume":"41","author":"Swanson","year":"2011","journal-title":"Am J Prev Med"},{"issue":"8","key":"2026051915113094300_bib6","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1007\/s12325-023-02545-7","article-title":"Economic and clinical burden of managing sickle cell disease with recurrent vaso-occlusive crises in the United States [published correction appears in Adv Ther. 2023;40(11):5130]","volume":"40","author":"Udeze","year":"2023","journal-title":"Adv Ther"},{"issue":"suppl 1","key":"2026051915113094300_bib7","doi-asserted-by":"crossref","first-page":"7662","DOI":"10.1182\/blood-2024-205210","article-title":"Real-world patient-reported sickle cell disease burden in the United States","volume":"144","author":"Barcelos","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026051915113094300_bib8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"2026051915113094300_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40265-020-01262-7","article-title":"Voxelotor: first approval","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"issue":"8","key":"2026051915113094300_bib10","doi-asserted-by":"crossref","first-page":"e29716","DOI":"10.1002\/pbc.29716","article-title":"Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years","volume":"69","author":"Estepp","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"2026051915113094300_bib11","unstructured":"US Food and Drug Administration\n          . FDA Approves Drug to Treat Sickle Cell Disease in Patients Aged 4 Up to 11 Years. Accessed 5 May 2025. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-treat-sickle-cell-disease-patients-aged-4-11-years."},{"key":"2026051915113094300_bib12","unstructured":"BioSpace\n          . GBT and Biopharma-MEA Enter Agreement to Distribute Oxbryta\u00ae (Voxelotor) in Six Middle Eastern Countries. Accessed 23 June 2025. https:\/\/www.biospace.com\/gbt-and-biopharma-mea-enter-agreement-to-distribute-oxbryta-voxelotor-in-six-middle-eastern-countries."},{"issue":"1","key":"2026051915113094300_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jha2.831","article-title":"Voxelotor improves red blood cell functionality in children with sickle cell anaemia: an ancillary study of the HOPE-KIDS 1 trial","volume":"5","author":"Chonat","year":"2024","journal-title":"EJHaem"},{"key":"2026051915113094300_bib14","unstructured":"European Medicines Agency\n          . EMA Starts Review of Sickle Cell Disease Medicine Oxbryta. Review Follows Reports of Fatal Cases in Clinical Trials. Accessed 23 June 2025. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/oxbryta-article-20-procedure-review-started_en.pdf."},{"key":"2026051915113094300_bib15","unstructured":"Pfizer\n          . Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment Oxbryta\u00ae (Voxelotor) From Worldwide Markets. Accessed 20 April 2025. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease."},{"key":"2026051915113094300_bib16","unstructured":"European Medicines Agency\n          . Oxbryta Article-20 Procedure - Assessment Report on Temporary Measures. Accessed 23 June 2025. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/oxbryta-article-20-procedure-assessment-report-temporary-measures_en.pdf."},{"issue":"5","key":"2026051915113094300_bib17","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1007\/s12325-025-03162-2","article-title":"Impact of different definitions of vaso-occlusion on efficacy assessments in sickle cell disease clinical trials","volume":"42","author":"Frangoul","year":"2025","journal-title":"Adv Ther"},{"issue":"5","key":"2026051915113094300_bib18","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/S2352-3026(21)00059-4","article-title":"Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Howard","year":"2021","journal-title":"Lancet Haematol"},{"issue":"2","key":"2026051915113094300_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/ejh.13782","article-title":"Real-world data on voxelotor to treat patients with sickle cell disease","volume":"109","author":"Muschick","year":"2022","journal-title":"Eur J Haematol"},{"key":"2026051915113094300_bib20","unstructured":"US Food and Drug Administration\n          . FDA Is Alerting Patients And Health Care Professionals About the Voluntary Withdrawal of Oxbryta From the Market Due to Safety Concerns. Accessed 23 June 2025. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due."},{"issue":"12","key":"2026051915113094300_bib21","doi-asserted-by":"crossref","first-page":"e240232","DOI":"10.57264\/cer-2024-0232","article-title":"Adherence, treatment utilization, clinical and economic outcomes of patients with sickle cell disease with recurrent vaso-occlusive crises treated with recently approved chronic therapies in the US","volume":"14","author":"Udeze","year":"2025","journal-title":"J Comp Eff Res"},{"issue":"1","key":"2026051915113094300_bib22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12873-024-01043-5","article-title":"Emergency department utilization before and during the COVID-19 pandemic among individuals with sickle cell disease","volume":"24","author":"Attell","year":"2024","journal-title":"BMC Emerg Med"},{"issue":"3","key":"2026051915113094300_bib23","doi-asserted-by":"crossref","first-page":"e045343","DOI":"10.1136\/bmjopen-2020-045343","article-title":"Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review","volume":"11","author":"Moynihan","year":"2021","journal-title":"BMJ Open"},{"issue":"suppl 1","key":"2026051915113094300_bib24","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1182\/blood-2021-151375","article-title":"Impact of COVID 19 pandemic on health care utilization for patients with sickle cell disease - a specialty treatment center experience","volume":"138","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2026051915113094300_bib25","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/13696998.2020.1813144","article-title":"Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers","volume":"23","author":"Shah","year":"2020","journal-title":"J Med Econ"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3032\/2515913\/blooda_adv-2025-018992-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3032\/2515913\/blooda_adv-2025-018992-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:11:40Z","timestamp":1779217900000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/3032\/566639\/Safety-and-effectiveness-of-voxelotor-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018992","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,4,30]]}}}